GoAI
Get started
Apollomics, Inc. logo

Apollomics, Inc.

APLM

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$24.3268

+$0.7568 · +3.21%

Aug 21, 4:00 PM ET

APLM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

56

Fair Value

Momentum

49

Neutral

Sentiment

53

Mixed

Risk resilience

25

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Hung-Wen Chen
Listed since
Nov 26, 2021
Employees
14

Market position

Day range

Current $24.3268

52-week range

Current $24.3268

Open
$22.93
Previous close
$23.57
Volume
6.27K
0.33× average
Average volume
19.27K
Average daily volume
Market cap
53.42M USD
Beta
1.45
Market reference 1
50-day average
$18.8462
+29.08% above average
200-day average
$17.51
+38.93% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
24.39M USD
P/E (TTM)
-3.21×
P/B (TTM)
-3.21×
P/S (TTM)
6.29×
EV / EBITDA
-2.65×
Earnings yield
-40.48%
Free cash flow yield
-38.37%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-111.45%
Net margin
-128.69%
Return on equity
343.13%
Return on assets
-162.93%
Return on invested capital
-1586.77%

Financial health

Debt / equity
-0.2×
Current ratio
0.96×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends474095%-1421885%-3317865%-5213845%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 97.00%Operating margin, FY2021: -2542850.00%Operating margin, FY2022: -13956.97%Operating margin, FY2023: -6578.93%Operating margin, FY2024: -21280.81%Operating margin, FY2025: -111.45%Net margin, FY2021: -4739850.00%Net margin, FY2022: -74554.49%Net margin, FY2023: -21023.26%Net margin, FY2024: -27201.01%Net margin, FY2025: -128.69%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 97.00%. Operating margin FY2021 -2542850.00%. Operating margin FY2022 -13956.97%. Operating margin FY2023 -6578.93%. Operating margin FY2024 -21280.81%. Operating margin FY2025 -111.45%. Net margin FY2021 -4739850.00%. Net margin FY2022 -74554.49%. Net margin FY2023 -21023.26%. Net margin FY2024 -27201.01%. Net margin FY2025 -128.69%.

Income trends

Revenue

8.5M USD+4192.93%

Operating income

−9.47M USD+77.52%

Net income

−10.94M USD+79.69%
Income trends across reported periods33.43M USD−66.29M USD−166.02M USD−265.74M USDRevenue, FY2021: 2K USDRevenue, FY2022: 323K USDRevenue, FY2023: 821K USDRevenue, FY2024: 198K USDRevenue, FY2025: 8.5M USDOperating income, FY2021: −50.86M USDOperating income, FY2022: −45.08M USDOperating income, FY2023: −54.01M USDOperating income, FY2024: −42.14M USDOperating income, FY2025: −9.47M USDNet income, FY2021: −94.8M USDNet income, FY2022: −240.81M USDNet income, FY2023: −172.6M USDNet income, FY2024: −53.86M USDNet income, FY2025: −10.94M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2K USD. Revenue FY2022 323K USD. Revenue FY2023 821K USD. Revenue FY2024 198K USD. Revenue FY2025 8.5M USD. Operating income FY2021 −50.86M USD. Operating income FY2022 −45.08M USD. Operating income FY2023 −54.01M USD. Operating income FY2024 −42.14M USD. Operating income FY2025 −9.47M USD. Net income FY2021 −94.8M USD. Net income FY2022 −240.81M USD. Net income FY2023 −172.6M USD. Net income FY2024 −53.86M USD. Net income FY2025 −10.94M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue8.5M USD198K USD821K USD323K USD2K USD
Cost of goods sold255K USD————
Gross profit8.25M USD198K USD821K USD323K USD2K USD
Research and development5.53M USD24.57M USD34.19M USD35.46M USD35.57M USD
Selling, general, and administrative12.44M USD17.77M USD20.64M USD9.95M USD15.29M USD
Operating expenses17.72M USD42.33M USD54.83M USD45.4M USD50.86M USD
Interest income152K USD480K USD753K USD431K USD467K USD
Interest expense65K USD179K USD150K USD93K USD83K USD
Depreciation and amortization255K USD72K USD103K USD182K USD153K USD
Operating income−9.47M USD−42.14M USD−54.01M USD−45.08M USD−50.86M USD
Net income−10.94M USD−53.86M USD−172.6M USD−240.81M USD−94.8M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
33%
1 beat, 2 misses, 0 met estimates
Average EPS surprise
-58025.29%
3 comparable reports
Latest EPS result
3.8

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates7.11-8.88-24.88-40.87Q2 '23BeatQ3 '23MissQ1 '24MissQ3 '24No estimateQ2 '25No estimateQ3 '25No estimateQ2 '26No estimate
Q2 2023, reported Apr 28, 2023: actual -0.001, estimate -0.16, surprise +99.13%, Beat. Q3 2023, reported Sep 28, 2023: actual -2.55, estimate -0.002, surprise -159275.00%, Miss. Q1 2024, reported Mar 28, 2024: actual -24, estimate -0.16, surprise -14900.00%, Miss. Q3 2024, reported Aug 14, 2024: actual -37.56, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 3, 2025: actual -16.92, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Jul 3, 2025: actual -11.37, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 27, 2026: actual 3.8, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates9.31M5.41M1.52M-2.38MQ2 '23Q3 '23Q1 '24Q3 '24Q2 '25Q3 '25
Q2 2023, reported Apr 28, 2023: actual -272K USD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Sep 28, 2023: actual 488K USD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual 333K USD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 14, 2024: actual 1.77M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 3, 2025: actual -1.57M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Jul 3, 2025: actual 8.5M USD, estimate —, surprise —, Comparison unavailable.

APLM news

globenewswire.com

Apollomics Announces $10 Million Private Placement Transaction

FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to…

Read source
globenewswire.com

Apollomics Regains Full Compliance with Nasdaq Listing Requirements

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to…

Read source
globenewswire.com

Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia

FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to…

Read source

APLM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research APLM

research.disclaimer